[go: up one dir, main page]

AR072185A1 - Agonistas de receptores s1p1 y uso de los mismos - Google Patents

Agonistas de receptores s1p1 y uso de los mismos

Info

Publication number
AR072185A1
AR072185A1 ARP090102221A ARP090102221A AR072185A1 AR 072185 A1 AR072185 A1 AR 072185A1 AR P090102221 A ARP090102221 A AR P090102221A AR P090102221 A ARP090102221 A AR P090102221A AR 072185 A1 AR072185 A1 AR 072185A1
Authority
AR
Argentina
Prior art keywords
alkyl
haloalkyl
substituted
cr10r10
formula
Prior art date
Application number
ARP090102221A
Other languages
English (en)
Inventor
Kelvin K C Sham
Victor J Cee
Brian Alan Lanman
Anthony B Reed
Susana C Neira
Michael J Frohn
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR072185A1 publication Critical patent/AR072185A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)

Abstract

La presente se refiere a compuestos que tienen actividad como agentes moduladores del receptor S1P, m s espec¡ficamente a compuestos que son agonistas del receptor S1P1. La presente tambien se refiere al uso de dichos compuestos para tratar enfermedades asociadas con la actividad inapropiada del receptor S1P1, tales como enfermedades autoinmunes. Reivindicacion 1: Un compuesto de formula (1) en donde m es 0, 1, 2 o 3; n es 0, 1, 2 o 3; o es 0, 1, 2 o 3; A es un fenilo, heterociclilo, cicloalquilo de tres a seis miembros, o un anillo heteroarilo de cinco o seis miembros; L es un anillo saturado de 3, 4, 5, 6 o 7 miembros que contiene 0, 1 o 2  tomos seleccionados de N, O y S y que opcionalmente contiene un doble enlace, estando sustituido el anillo por 0, 1 o 2 grupos seleccionados de F, Cl, alquilo C1-4, haloalquilo C1-4, OH, alquilo-O C1-4, y haloalquilo-O C1-4 X1 es N o CH; X2 es N o CH; X5 es N o CH; el grupo de formula (2) se selecciona entre los compuestos de formula (3), (4), (5), (6), (7), (8) y (9); R1 se selecciona de F, Cl, alquilo C1-4, haloalquilo C1-4, OH, alquilo-O C1-4, y haloalquilo-O C1-4; R2 se selecciona de F, Cl, alquilo C1-4, haloalquilo C1-4, OH, alquilo-O C1-4, y haloalquilo-O C1-4, R3 se selecciona de F, Cl, alquilo C1-4, haloalquilo C1-4, OH, alquilo-O C1-4, amino y haloalquilo-O C1-4; Z es: (i) un cicloalquilo sustituido con un grupo amino, monoalquilamino o dialquilamino; un cicloalquilalquilo sustituido con uno o dos grupos carboxi; un grupo amino monosustituido, amino disustituido, carboxialquilamino, hidroxialquilo, hidroxialquilo sustituido, hidroxialcoxi, hidroxialcoxi sustituido, aminoalquilo, aminoalcoxi, carboxialquilo, carboxialquilo sustituido, carboxialquiloxi, carboxialquiloxi sustituido, carboxialcoxialquilo, carboxialcoxialquilo sustituido, aminocarbonilo, acilamino, sulfonilamino, heterocicloamino, heterocicloaminoalquilo, heterocicloaminocarbonilo, heterocicloaminoxi, o heteroaralquilo; (ii) un grupo de formula (10) donde: q es 0, 1 o 2; R4 se selecciona de H, haloalquilo C1-3, alquilo C1-6; R5 se selecciona de H, haloalquilo C1-3, alquilo C1-4; o R4 y R5 junto con el  tomo de carbono al cual est n unidos forman un anillo carboc¡clico de 3, 4, 5, 6 o 7 miembros sustituido por 0, 1 o 2 grupos seleccionados de F, CI, alquilo C1-4, haloalquilo C1-4, OH, alquilo-O C1-4, y haloalquilo-O C1-4; R6 es un par solitario de electrones o O; R7 es H o alquilo C1-6; R8 se selecciona de H, F, Cl, alquilo C1-4, haloalquilo C1-4, OH, alquilo-O C1-4, y haloalquilo-O C1-4 o R7 y R8, cuando se toman juntos, forman un grupo que se selecciona de -(CR10R10)-, -(CR10R10)O-, -O(CR10R10)-, -(CR10R10)(CR10R10)-, y -(CR10R10)3-; R9 se selecciona de H, F, haloalquilo C1-3, alquilo C1-4, OH y alquilo-O C1-4; o R8 y R9 junto con el  tomo de carbono al cual est n unidos forman cicloalquilo; y cada R10 es independientemente en cada instancia seleccionado a partir de H, F, CI, alquilo C1-4, haloalquilo C1-4, OH, alquilo-O C1-4, y haloalquilo-O C1-4 o (iii) cuando R3 est  sobre un  tomo de carbono del anillo fenilo que es adyacente al carbono del anillo fenilo que est  unido a Z, entonces R3 y Z pueden combinarse para formar -CH=CH-NR11, -(CH2)2NR11-, -CH2NR11CH2-, -(CH2)2NR11CH2-, -N=CR11-NH-, o -N=CH-NR11-, donde R11 se selecciona de hidrogeno, hidroxialquilo, aminoalquilo, carboxialquilo, hidroxialquilo sustituido, carboxialquilo sustituido, o aminocarbonilo; o una farmaceuticamente aceptable del mismo; siempre que cuando el compuesto de formula (2) se selecciona de los compuestos de formula (6), (7), (8) y (9), entonces al menos uno de X1, X2 y X5 es N.
ARP090102221A 2008-06-20 2009-06-18 Agonistas de receptores s1p1 y uso de los mismos AR072185A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7447608P 2008-06-20 2008-06-20

Publications (1)

Publication Number Publication Date
AR072185A1 true AR072185A1 (es) 2010-08-11

Family

ID=41434357

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102221A AR072185A1 (es) 2008-06-20 2009-06-18 Agonistas de receptores s1p1 y uso de los mismos

Country Status (10)

Country Link
US (2) US20120129828A1 (es)
EP (1) EP2306994B1 (es)
JP (1) JP5571073B2 (es)
AR (1) AR072185A1 (es)
AU (1) AU2009260726B2 (es)
CA (1) CA2728046A1 (es)
ES (1) ES2433579T3 (es)
MX (1) MX2010013555A (es)
TW (1) TW201000099A (es)
WO (2) WO2009154780A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33176A (es) * 2010-01-13 2011-08-31 Sanofi Aventis Derivados de oxazolopirimidina sustituida en 2, 5, 7.
TWI517851B (zh) * 2010-01-13 2016-01-21 賽諾菲阿凡提斯公司 含２，５，７－經取代唑并嘧啶環之雜環羧酸衍生物
TWI478929B (zh) 2010-01-13 2015-04-01 Sanofi Aventis 含２，５，７－經取代唑并嘧啶環之羧酸衍生物
SG182484A1 (en) * 2010-01-14 2012-08-30 Sanofi Sa Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring
WO2011086081A1 (de) 2010-01-14 2011-07-21 Sanofi-Aventis 2,5-substituierte oxazolopyrimidinderivate
MY156476A (en) 2010-01-14 2016-02-26 Sanofi Sa Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring
TW201206429A (en) * 2010-07-08 2012-02-16 Merck Serono Sa Substituted oxadiazole derivatives
BR112013006016A2 (pt) 2010-09-15 2016-06-07 Hoffmann La Roche compostos de azabenzotiazol, composições e métodos de uso
EP2688882B1 (en) * 2011-03-25 2015-05-13 Boehringer Ingelheim International GmbH Pyrazole compounds as crth2 antagonists
US8735402B2 (en) * 2011-07-07 2014-05-27 Sanofi Cycloalkyloxycarboxylic acid derivatives
US8580816B2 (en) 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
US9321787B2 (en) 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
US8907093B2 (en) * 2011-07-07 2014-12-09 Sanofi Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
WO2013158422A1 (en) 2012-04-17 2013-10-24 E. I. Du Pont De Nemours And Company Heterocyclic compounds for controlling invertebrate pests
CN104380596B (zh) * 2012-07-20 2018-01-02 三菱电机株式会社 保持框架和太阳能电池模块
CA2901527A1 (en) 2013-02-20 2014-08-28 Bayer Pharma Aktiengesellschaft Substituted-imidazo[1,2-b]pyridazines as mknk1 inhibitors
HK1225716A1 (zh) 2013-08-21 2017-09-15 Alios Biopharma, Inc. 抗病毒化合物
US10597401B2 (en) 2015-05-08 2020-03-24 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
IL252151A0 (en) 2017-05-07 2017-07-31 Fainzilber Michael Treatment of stress disorders
IL271149B2 (en) * 2017-06-14 2024-05-01 Trevena Inc Compounds for modulating s1p1 activity and methods of using the same
CN110256466A (zh) * 2019-07-31 2019-09-20 昆山迪安医学检验实验室有限公司 一种噻唑[5,4-b]-吡啶基生物活性化合物的制备方法及其抗肿瘤活性的检测
JP2023502123A (ja) 2019-11-19 2023-01-20 トレベナ・インコーポレイテッド Ｓ１ｐ１モジュレーター化合物及び化合物を調製する方法
CN115611793A (zh) * 2021-07-14 2023-01-17 山东新华制药股份有限公司 硫代酰胺类化合物的合成方法
CN116410213A (zh) * 2023-02-21 2023-07-11 武汉大学 一种合成3-碳基-1-硼基环类化合物的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
ATE420869T1 (de) 2000-10-05 2009-01-15 Takeda Pharmaceutical Promotoren zur proliferation und differenzierung von stammzellen und/oder vorstufen von neuronenzellen
EP1377549A1 (en) 2001-03-12 2004-01-07 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
AU2002349477A1 (en) 2001-11-26 2003-06-10 Takeda Chemical Industries, Ltd. Bicyclic derivative, process for producing the same, and use
WO2003062252A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
CA2523677A1 (en) * 2003-04-30 2004-11-11 Novartis Ag Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
WO2004098494A2 (en) 2003-04-30 2004-11-18 Cytokinetics, Inc. Compounds, compositions, and methods
PE20050158A1 (es) * 2003-05-19 2005-05-12 Irm Llc Compuestos inmunosupresores y composiciones
WO2006044456A1 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
JP2009520688A (ja) 2005-11-23 2009-05-28 エピックス デラウェア， インコーポレイテッド Ｓ１ｐ受容体調節化合物およびそれらの使用
US7919519B2 (en) * 2005-11-23 2011-04-05 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
WO2007084857A2 (en) 2006-01-13 2007-07-26 President And Fellows Of Harvard College Methods and compositions for treating cell proliferative disorders
US8003662B2 (en) 2006-01-30 2011-08-23 Array Biopharma, Inc. Heterobicyclic thiophene compounds and methods of use
JP4897834B2 (ja) 2006-02-08 2012-03-14 コダック グラフィック コミュニケーションズ ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンゾキサゾール誘導体およびその類似体を増感剤として含む紫外線感受性平版印刷版前駆体
TW200806633A (en) 2006-03-21 2008-02-01 Epix Pharm Inc S1P receptor modulating compounds and use thereof
CA2645639A1 (en) * 2006-03-23 2007-10-04 Merck & Co. Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US20100055071A1 (en) 2006-11-21 2010-03-04 Martin Robert Leivers Anti-Viral Compounds
CN101600437A (zh) 2006-12-11 2009-12-09 诺瓦提斯公司 预防或治疗心肌缺血的方法
MX2009010060A (es) * 2007-03-21 2010-01-20 Epix Pharm Inc Compuestos moduladores del receptor de esfingosin-1-fosfato y uso de los mismos.
JP2008308448A (ja) 2007-06-15 2008-12-25 Sankyo Agro Kk （３−硫黄原子置換フェニル）へテロアリール誘導体
EP2188252B1 (en) 2007-09-20 2011-04-13 Amgen Inc. 1-(4-(4-benzylbenzamido)-benzyl)azetidine-3-carboxylic acid derivatives and related compounds as s1p receptor modulators for the treatment of immune disorders

Also Published As

Publication number Publication date
EP2306994A4 (en) 2011-08-03
JP5571073B2 (ja) 2014-08-13
AU2009260726A1 (en) 2009-12-23
EP2306994A1 (en) 2011-04-13
MX2010013555A (es) 2011-01-14
WO2009154780A1 (en) 2009-12-23
ES2433579T3 (es) 2013-12-11
TW201000099A (en) 2010-01-01
EP2306994B1 (en) 2013-08-14
US7842685B2 (en) 2010-11-30
JP2011524906A (ja) 2011-09-08
US20120129828A1 (en) 2012-05-24
AU2009260726B2 (en) 2014-03-27
US20100029611A1 (en) 2010-02-04
CA2728046A1 (en) 2009-12-23
WO2009154775A1 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
AR072185A1 (es) Agonistas de receptores s1p1 y uso de los mismos
DK2990400T3 (da) Dicarboxylsyreforbindelse
PH12013502463A1 (en) Trpv4 antagonists
AR082138A1 (es) 1-hidroxiimino-3-fenil-propanos
ES2770058T3 (es) Compuestos y composiciones destinados a modular las actividades de quinasa de EGFR mutante
AR057702A1 (es) Inhibidores macrociclicos del virus de la hepatitis c, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para la profilaxis o el tratamiento de infecciones por flavivirus
AR071763A1 (es) Pirazoles trisustituidos, composiciones farmaceuticas que los contienen, y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos
AR055212A1 (es) Compuestos heterociclicos como bloqueantes del canal ionico p2x7
GEP201606526B (en) 5-ht3 receptor antagonists
BR112015001502A2 (pt) derivados de tipo azaindazol ou diazaindazol para tratamento de dor
AR060535A1 (es) Pirido-piridazinonas y ftalazinonas como antagonistas duales de los receptores h1 y h3 de histamina
BR112014023384A2 (pt) inibidores de bace de di-hidro-tiazina e di-hidro-oxazina espirocíclicos, e composições e usos dos mesmos
MX2012012421A (es) Compuestos tetrahidrobenzotiofena.
AR054485A1 (es) ARIL-ALQUILAMINAS Y HETEROARIL-ALQUILAMINAS COMO INHIBIDORES DE PROTEINA QUINASA A Y B, UN PROCESO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LAS CONTIENEN Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES ORIGINADAS EN EL CRECIMIENTO ANORMAL DE LA
AR061015A1 (es) Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto
ECSP099216A (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112014031091A2 (pt) Derivados de piperidina para agonista de gpr119
AR118983A1 (es) Antagonistas cíclicos del receptor b2 de bradiquinina
MX385276B (es) Tratamiento para la enfermedad de parkinson
UY37981A (es) Novedosos antagonistas del receptor b2 de bradiquinina
UY28861A1 (es) Nuevas combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
MX2012009224A (es) Compuestos en calidad de antagonistas de bradiquinina-b1.
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
EA201500375A1 (ru) Композиция для ухода за ротовой полостью
MX2024005670A (es) Analogos deuterados de acetil-leucina.

Legal Events

Date Code Title Description
FB Suspension of granting procedure